Advanced Search

Journal of Traditional Chinese Medicine >

2022 , Vol. 42 >Issue 3: 400 - 407

DOI: https://doi.org/10.19852/j.cnki.jtcm.20220311.004

Research Article

Mechanism underlying efficacy of Shugan Sanjie decoction (疏肝散结汤) on plasma cell mastitis, based on network pharmacology and experimental verification

  • Nan QIAO ,
  • Qinnan WANG ,
  • Chaoqun MA ,
  • Dexuan CHEN ,
  • Haidong CHEN ,
  • Yaoyao LU
Expand
  • 1 Department of general surgery, Nantong Hospital Affiliated to Nanjing University of Chinese Medicine, Nantong 226001, China
    2 Department of science and education, Affiliated Nantong Hospital of Shanghai University, Nantong 226000, China
    3 Department of general surgery, Affiliated Hospital to Nanjing University of Chinese Medicine, Nanjing 210029, China
MA Chaoqun, Department of general surgery, Affiliated Hospital to Nanjing University of Chinese Medicine, Nanjing 210029, China. mcq_1964@sina.com.Telephone: +86-18251313699

Received date: 2021-04-12

  Accepted date: 2021-07-25

  Online published: 2022-03-11

Supported by

Clinical Medicine Project of Nantong University for Youth(2019LQ018);Youth Project of Nantong Municipal Health Committee(QA2020013);Grants-in-Aid for Scientific Research from the Ministry of Nantong Science and Technology(MSZ18254)

Fold

Abstract

OBJECTIVE: To investigate the mechanism underpinning the effeicay of Shugan Sanjie decoction (疏肝散结汤, SGSJD) on plasma cell mastitis (PCM) based on network pharmacology, and to verify it through in vitro.

METHODS: Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform and Bioinformatics Analysis Tool for Molecular mechanism of Traditional Chinese Medicine were used to screen effective compounds and drug targets; Online Mendelian Inheritance in Man and GeneCards were used to search for PCM targets. The potential targets of SGSJD in treating PCM were obtained after the drug targets and disease targets were crossed. Cytoscape software was used to establish and analyze the network of Chinese medicines-active compounds-targets-disease; STRING database platform was used to analyze Protein Protein Interaction network; Bioconductor software package was used to perform Gene ontology and Kyoto Encyclopedia of Genes and Genomes enrichment for potential targets. Western blot analysis was used to verify the janus kinase/signal transducer and activator of transcription (JAK-STAT) pathway in vitro.

RESULTS: (a) 47 potential pharmacological components of SGSJD treatment of PCM were screened including quercetin, luteolin, kaempferol and others; 20 common targets were obtained, including interleukin-6 (IL-6), epidermal growth factor receptor, estrogen receptor 1, nitric oxide synthase 3 and others; a number of signal pathways were available, of which advanced glycation end product/ receptor for advanced glycation end products signaling pathway in diabetic complications, hypoxia-inducible factor 1 signaling pathway and janus tyrosine kinase-signal transducer and transcription activator (JAK-STAT) signaling pathway were the main signal pathways related to PCM. (b) Compared with the Blank group, the expressions of p-JAK2/JAK2, p-STAT3/STAT3 and IL-6 protein in the Model group were significantly increased (P < 0.01); Compared with the Model group, the expression of p-JAK2/JAK2, p-STAT3/STAT3, and IL-6 protein in the treatment group were significantly reduced in a dose-dependent manner (P < 0.05). Compared with the Model group, the dexamethasone significantly reduced the expression of p-JAK2/JAK2, p-STAT3/STAT3, and IL-6 (P < 0.01).

CONCLUSIONS: The SGSJD may regulate the JAK-STAT signaling pathway to achieve the effect of treating PCM by reducing the expression of p-JAK2/JAK2, p-STAT3/STAT3 and IL-6 in a dose-dependent manner.

Key words： plasma cells; mastitis; network pharmacology; molecular mechanism; Shugan Sanjie decoction

Cite this article

Nan QIAO , Qinnan WANG , Chaoqun MA , Dexuan CHEN , Haidong CHEN , Yaoyao LU . Mechanism underlying efficacy of Shugan Sanjie decoction (疏肝散结汤) on plasma cell mastitis, based on network pharmacology and experimental verification[J]. Journal of Traditional Chinese Medicine, 2022 , 42(3) : 400 -407 . DOI: 10.19852/j.cnki.jtcm.20220311.004

References

1 Ortiz-Mendoza CM, Sánchez NAA, Dircio AC. Fine-needle aspiration cytology to identify a rare mimicker of breast cancer: plasma cell mastitis. Rev Bras Ginecol Obstet 2018; 40:491-3.
2 Ren FL, Cai XJ. Progress in research of Traditional Chinese And Western Medicine in plasma cell mastitis. Xian Dai Zhong Xi Yi Jie He Za Zhi 2018; 27:3303-6.
3 Liu YF, An T, Wang CH, Zhang XM, Xiao JH, Pei XH. Progress on Traditional Chinese Medicine in treatment of plasma cell mastitis. Zhong Yi Xue Bao 2019; 34:289-93.
4 Ding XW, Fang Y. 92 Cases of mammary duct dilatation treated with Shugan Sanjie decoction. Jiangxi Zhong Yi Yao 2015; 46:54-6.
5 Qiao N, Ding XW, Shen H, Ni YS, Fang Y. Clinical observation on the treatment of non-puerperal mastitis in tumor stage by Integrated Chinese and Western Medicine. Zhong Guo Zhong Xi Yi Jie He Wai Ke Za Zhi 2020; 26:941-4.
6 Long HP, Lin XY, Wang YH, Ren WQ, Tan YS. Explore mechanism of compound uncaria hypotensive tablet for hypertension based on network pharmacology. Zhong Guo Zhong Yao Za Zhi 2018; 43:1360-5.
7 Wang J, Chen YW, Zhao K, Zhao GY, Jiang WW. Study on the molecular mechanism of Zuojin pills in the treatment of hypertension based on network pharmacology. Zhong Cheng Yao 2019; 41:1976-81.
8 Malley MJ. Isolation,culture and analysis of mouse mammary epithelial cells. Methods Mol Biol 2010; 633:139-70.
9 Lin J, Wu G, Chen J, et al. Electroacupuncture inhibits sodium nitroprusside-mediated chondrocyte apoptosis through the mitochondrial pathway Mol Med Rep 2018; 18:4922-30.
10 Ma N, Li YJ, Fan JP. Research progress on pharmacological action of quercetin. Liaoning Zhong Yi Yao Da Xue Xue Bao 2018; 20:221-4.
11 Yu Q, Wu GZ. Research progress of anti-inflammatory properties of luteolin. Yao Xue Yan Jiu 2019; 38:108-11.
12 Xiao WM, Bo P, Gong WJ. Advance in studies on antitumor and immunomodulatory effects of wogonin. Zhong Guo Zhong Yao Za Zhi 2014; 39:3004.
13 Zhang WJ, Zhen H. Progress of IL-6-mediated immuno-inflammatory response and its relationship with diseases. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi 2017; 33:699-703.
14 Li L, Zhang HC. Progress on the relationship between IL-6 and its JAK-STAT3 signaling pathway and myocardial remodeling. Kong Jun Yi Xue Za Zhi 2009; 25:23-5.
15 Huang TY, Li QZ, Hou XM. Progress on JAK-STAT function in mammary gland. Zhong Guo Ru Pin Gong Ye 2010; 38:41-4.
16 Yu B, Huang SH, Zhang TS, Wang Y. Interleukin-6 as a therapeutic target on inflammatory disease and Castleman's disease. Wu Jing Hou Qin Xue Yuan Xue Bao 2017; 26:634-6.
Options
Outlines

/

〈 〉